Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results

Neuroscientific Biopharmaceuticals

13/01/2026 02:47

** Shares of NeuroScientific Biopharmaceuticals NSB.AX rise as much as 52.2% to A$0.175, their highest level since September 24, 2025

** Biopharmaceutical co heading for best day since April 2025, if current gains hold

** Co announces successful clinical results from fistulising crohn's disease patients treated with its StemSmart mesenchymal stem cell therapy

** Says three of four patients demonstrated successful clinical response when treated with StemSmart

** About 4.3 mln shares change hands, 25.7x the 30-day average, in the busiest day since July 24, 2025

** Stock more than tripled in value last year

 (Reporting by John Biju in Bengaluru)

 ((John.Biju@thomsonreuters.com;))